Log in

NASDAQ:OSUROraSure Technologies Stock Price, Forecast & News

$13.41
-1.14 (-7.84 %)
(As of 08/12/2020 04:00 PM ET)
Add
Compare
Today's Range
$13.35
Now: $13.41
$14.49
50-Day Range
$9.71
MA: $14.28
$19.58
52-Week Range
$5.23
Now: $13.41
$19.75
Volume2.69 million shs
Average Volume1.32 million shs
Market Capitalization$959.59 million
P/E RatioN/A
Dividend YieldN/A
Beta0.67
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Its principal products include OraQuick ADVANCE HIV-1/2, OraQuick HIV-1/2, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV, OraQuick Ebola, OraQuick Zika, OraSure QuickFlu Rapid Flu A&B test, OraSure, Oragene DX, Oragene DNA, Oragene RNA, ORAcollect DX, ORAcollect DNA, Performagene, OMNIgene GUT, OMNIgene SPUTUM, OMNIgene VAGINAL, OMNIgene ORAL, GenoFIND, Hemagene, PrepIT, Intercept, MICRO-PLATE DOA assays, Intercept i2, homogeneous DOA assays, and professional and over-the-counter cryosurgical systems. In addition, the company manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome, and animal genetics markets. Further, it provides medical devices for the removal of benign skin lesions by cryosurgery or freezing; immunoassay tests and reagents for insurance risk assessment, substance abuse testing, and forensic toxicology applications; an oral fluid Western blot confirmatory test for confirming positive HIV-1 test; and Q.E.D. rapid point-of-care saliva alcohol test. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. OraSure Technologies, Inc. was founded in 2000 and is based in Bethlehem, Pennsylvania.
Read More
OraSure Technologies logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.3Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.34 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
Current SymbolNASDAQ:OSUR
CUSIP68554V10
Phone610-882-1820

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$154.60 million
Cash Flow$0.24 per share
Book Value$4.98 per share

Profitability

Net Income$16.66 million

Miscellaneous

Employees398
Market Cap$959.59 million
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$13.41
-1.14 (-7.84 %)
(As of 08/12/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive OSUR News and Ratings via Email

Sign-up to receive the latest news and ratings for OSUR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











OraSure Technologies (NASDAQ:OSUR) Frequently Asked Questions

How has OraSure Technologies' stock been impacted by Coronavirus?

OraSure Technologies' stock was trading at $5.90 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, OSUR stock has increased by 127.3% and is now trading at $13.41.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of OraSure Technologies?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OraSure Technologies in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for OraSure Technologies
.

When is OraSure Technologies' next earnings date?

OraSure Technologies is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for OraSure Technologies
.

How were OraSure Technologies' earnings last quarter?

OraSure Technologies, Inc. (NASDAQ:OSUR) posted its quarterly earnings data on Wednesday, August, 5th. The medical instruments supplier reported ($0.16) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.10) by $0.06. OraSure Technologies had a negative return on equity of 3.08% and a negative net margin of 1.57%.
View OraSure Technologies' earnings history
.

What price target have analysts set for OSUR?

6 equities research analysts have issued twelve-month price objectives for OraSure Technologies' shares. Their forecasts range from $8.00 to $19.00. On average, they expect OraSure Technologies' share price to reach $15.50 in the next year. This suggests a possible upside of 15.6% from the stock's current price.
View analysts' price targets for OraSure Technologies
.

Has OraSure Technologies been receiving favorable news coverage?

News coverage about OSUR stock has been trending extremely negative recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. OraSure Technologies earned a media sentiment score of -4.1 on InfoTrie's scale. They also gave media stories about the medical instruments supplier a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the near term.
View the latest news about OraSure Technologies
.

Are investors shorting OraSure Technologies?

OraSure Technologies saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 3,100,000 shares, an increase of 35.4% from the April 15th total of 2,290,000 shares. Based on an average daily trading volume, of 1,070,000 shares, the days-to-cover ratio is currently 2.9 days.
View OraSure Technologies' Short Interest
.

Who are some of OraSure Technologies' key competitors?

What other stocks do shareholders of OraSure Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OraSure Technologies investors own include Merit Medical Systems (MMSI), Citigroup (C), XOMA (XOMA), Energy Transfer LP Unit (ET), Overstock.com (OSTK), Ford Motor (F), Chesapeake Energy (CHKAQ), Chesapeake Energy (CHKAQ), Pfizer (PFE) and Abbott Laboratories (ABT).

Who are OraSure Technologies' key executives?

OraSure Technologies' management team includes the following people:
  • Dr. Stephen S. Tang, Pres, CEO & Director (Age 58)
  • Mr. Jack E. Jerrett, Sr. VP, Gen. Counsel & Sec. (Age 60)
  • Mr. Anthony Zezzo II, Exec. VP & Bus. Unit Leader of Infectious Disease (Age 65)
  • Mr. Brian L. Smith, Vice Chairman & EVP of Innovation - DNA Genotek, Inc. (Age 60)
  • Mr. Roberto E. Cuca, CFO & Principal Accounting Officer (Age 51)

What is OraSure Technologies' stock symbol?

OraSure Technologies trades on the NASDAQ under the ticker symbol "OSUR."

Who are OraSure Technologies' major shareholders?

OraSure Technologies' stock is owned by many different institutional and retail investors. Top institutional shareholders include Principal Financial Group Inc. (0.86%), Monashee Investment Management LLC (0.59%), WINTON GROUP Ltd (0.66%), Bank of Montreal Can (0.50%), Goldman Sachs Group Inc. (0.46%) and Fisher Asset Management LLC (0.40%). Company insiders that own OraSure Technologies stock include Charles W Patrick, Jack E Jerrett, Roberto Cuca and Stephen S Phd Tang.
View institutional ownership trends for OraSure Technologies
.

Which major investors are selling OraSure Technologies stock?

OSUR stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Sicart Associates LLC, Bank of Montreal Can, Fisher Asset Management LLC, First Hawaiian Bank, Quadrant Private Wealth Management LLC, Russell Investments Group Ltd., and Prudential Financial Inc..
View insider buying and selling activity for OraSure Technologies
.

Which major investors are buying OraSure Technologies stock?

OSUR stock was bought by a variety of institutional investors in the last quarter, including Monashee Investment Management LLC, Mackay Shields LLC, WINTON GROUP Ltd, SG Americas Securities LLC, Principal Financial Group Inc., Strs Ohio, Goldman Sachs Group Inc., and Jennison Associates LLC. Company insiders that have bought OraSure Technologies stock in the last two years include Jack E Jerrett, Roberto Cuca, and Stephen S Phd Tang.
View insider buying and selling activity for OraSure Technologies
.

How do I buy shares of OraSure Technologies?

Shares of OSUR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is OraSure Technologies' stock price today?

One share of OSUR stock can currently be purchased for approximately $13.41.

How big of a company is OraSure Technologies?

OraSure Technologies has a market capitalization of $959.59 million and generates $154.60 million in revenue each year. The medical instruments supplier earns $16.66 million in net income (profit) each year or $0.13 on an earnings per share basis. OraSure Technologies employs 398 workers across the globe.

What is OraSure Technologies' official website?

The official website for OraSure Technologies is www.orasure.com.

How can I contact OraSure Technologies?

OraSure Technologies' mailing address is 220 EAST FIRST STREET, BETHLEHEM PA, 18015. The medical instruments supplier can be reached via phone at 610-882-1820 or via email at [email protected]

This page was last updated on 8/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.